![]() ![]() The explosion of new products for the treatment of haemophilia will hopefully benefit all patients and change the current landscape from shortage, allowing only limited dosing in prophylactic regimens, to one of plenty. Now the landscape is changing dramatically. The Swedish and the Dutch groups have published the most comprehensive data on long term outcome with life-long prophylaxis. 1 Patients having access to primary prophylaxis are growing up without or with very limited joint problems. To prevent joint disease prophylaxis should be started very early, preferably after no more than 1-2 joint bleeds. Prophylaxis aimed at the prevention of bleeds is now globally accepted as the superior therapy. Only countries in the developed world with health-care systems that reimbursed the costs of treatment were able to start prophylaxis-based treatment regimens. Therefore, patients had no access to treatment at home and treatment was only delivered after long delays and more often not at all. ![]() ![]() It was therefore understandable that treatment choices were made based on shortage models. Even today many countries lack a continuously supply and patients are left without any choice. Introduction: Haemophilia treatment has long been hampered by the shortage of products. 00-Invited Presentation Summaries TU-PL-G – WFH VP Medical's Address New horizons within sight for haemophilia
0 Comments
Leave a Reply. |